Literature DB >> 21734353

Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy.

Norio Akuta1, Fumitaka Suzuki, Miharu Hirakawa, Yusuke Kawamura, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Satoshi Saitoh, Yasuji Arase, Kenji Ikeda, Kazuaki Chayama, Yusuke Nakamura, Hiromitsu Kumada.   

Abstract

OBJECTIVE: To evaluate predictive factors of treatment efficacy to interferon (IFN)/ribavirin in patients infected with HCV genotype 1b (HCV-1b).
METHODS: This study investigated pretreatment predictors, including viral- (aa substitutions in core aa 70/91 and NS5A-ISDR/IRRDR) and host-related factors (genetic variation near IL28B gene), to 48-week IFN/ribavirin in 490 Japanese adults infected with HCV-1b.
RESULTS: The proportion of patients who showed end-of-treatment response (ETR), sustained virological response (SVR), and SVR after ETR was 76, 54, and 76%, respectively. There was a significant positive correlation between the number of aa substitutions in ISDR and those in IRRDR. Concerning the substitution of core aa 91, the number of aa substitutions in ISDR/IRRDR of patients with Leu91 was significantly higher than that of patients with Met91. Furthermore, levels of viremia were influenced by aa substitutions in core aa 91 and ISDR/IRRDR. By multivariate analysis, rs8099917 genotype was an important predictor of ETR and SVR. With regard to viral factors, core aa 70/91 was an important predictor of ETR, and SVR after ETR. ISDR was an important predictor of SVR, and SVR after ETR.
CONCLUSION: aa substitution in core/NS5A region and genetic variation near IL28B were important predictors of treatment efficacy to IFN/ribavirin.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21734353     DOI: 10.1159/000328327

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  11 in total

Review 1.  Genetics of IL28B and HCV--response to infection and treatment.

Authors:  C Nelson Hayes; Michio Imamura; Hiroshi Aikata; Kazuaki Chayama
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-29       Impact factor: 46.802

Review 2.  Impact of host and virus genome variability on HCV replication and response to interferon.

Authors:  Cameron J Schweitzer; T Jake Liang
Journal:  Curr Opin Virol       Date:  2013-07-06       Impact factor: 7.090

Review 3.  Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.

Authors:  E Cariani; L Roli; G Missale; E Villa; C Ferrari; T Trenti
Journal:  Pharmacogenomics J       Date:  2015-04-28       Impact factor: 3.550

Review 4.  Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis.

Authors:  Simona Bota; Ioan Sporea; Roxana Şirli; Adriana Maria Neghină; Alina Popescu; Mihnea Străin
Journal:  Clin Drug Investig       Date:  2013-05       Impact factor: 2.859

5.  TRAIL dependent fratricidal killing of gp120 primed hepatocytes by HCV core expressing hepatocytes.

Authors:  Stacey A Rizza; Kishore B Challagundla; Sekar Natesampillai; Gary D Bren; Jaromir Sykora; Henning Walczak; Andrew D Badley
Journal:  PLoS One       Date:  2011-11-14       Impact factor: 3.240

6.  Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b-infected patients.

Authors:  Verónica Saludes; Elisabet Bascuñana; Elena Jordana-Lluch; Sònia Casanovas; Mercè Ardèvol; Esther Soler; Ramón Planas; Vicente Ausina; Elisa Martró
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

7.  Lack of Association between Hepatitis C Virus core Gene Variation 70/91aa and Insulin Resistance.

Authors:  Letícia de Paula Scalioni; Allan Peres da Silva; Juliana Custódio Miguel; Márcia Paschoal do Espírito Santo; Vanessa Alves Marques; Carlos Eduardo Brandão-Mello; Cristiane Alves Villela-Nogueira; Lia Laura Lewis-Ximenez; Elisabeth Lampe; Livia Melo Villar
Journal:  Int J Mol Sci       Date:  2017-07-21       Impact factor: 5.923

Review 8.  Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.

Authors:  Ahmed El-Shamy; Hak Hotta
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

9.  Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates.

Authors:  Rossana C Jaspe; Yoneira F Sulbarán; Maria Z Sulbarán; Carmen L Loureiro; Hector R Rangel; Flor H Pujol
Journal:  Virol J       Date:  2012-09-21       Impact factor: 4.099

10.  Predictors of response to 24-week telaprevir-based triple therapy for treatment-naïve genotype 1b chronic hepatitis C patients.

Authors:  Hiroshi Abe; Akihito Tsubota; Noritomo Shimada; Masanori Atsukawa; Keizo Kato; Koichi Takaguchi; Toru Asano; Yoshimichi Chuganji; Choitsu Sakamoto; Hidenori Toyoda; Takashi Kumada; Tatsuya Ide; Michio Sata; Yoshio Aizawa
Journal:  Gastroenterol Res Pract       Date:  2014-08-14       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.